These results were evaluated in a randomized phase 3 study (Destiny-Breast 02), comparing fam-trastuzumab deruxtecan with the treatment physician’s choice in patients with advanced HER2 breast cancer previously treated with trastuzumab emtansine [44]. Here, ERBB2 is linked to breast carcinoma.